These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 20184801)

  • 1. Erlotinib-associated near-fatal interstitial pneumonitis in a patient with relapsed lung adenocarcinoma.
    Chou CL; Ko HW; Wang CW; Yu CT; Kuo HP; Huang CD
    Chang Gung Med J; 2010; 33(1):100-5. PubMed ID: 20184801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.
    Makris D; Scherpereel A; Copin MC; Colin G; Brun L; Lafitte JJ; Marquette CH
    BMC Cancer; 2007 Aug; 7():150. PubMed ID: 17683587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review.
    Koma Y; Matsuoka H; Yoshimatsu H; Suzuki Y
    Int J Clin Pharmacol Ther; 2012 Oct; 50(10):760-4. PubMed ID: 22853866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Fatal interstitial lung disease associated with erlotinib use].
    Eshuis M; Ahsmann EJ; van Egmond NH
    Ned Tijdschr Geneeskd; 2013; 157(7):A5519. PubMed ID: 23406641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature.
    ter Heine R; van den Bosch RT; Schaefer-Prokop CM; Lankheet NA; Beijnen JH; Staaks GH; van der Westerlaken MM; Malingré MM; van den Brand JJ
    Lung Cancer; 2012 Mar; 75(3):391-7. PubMed ID: 22101147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
    Tammaro KA; Baldwin PD; Lundberg AS
    J Oncol Pharm Pract; 2005 Sep; 11(3):127-30. PubMed ID: 16390601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatal interstitial lung disease after erlotinib for non-small cell lung cancer.
    Lind JS; Smit EF; Grünberg K; Senan S; Lagerwaard FJ
    J Thorac Oncol; 2008 Sep; 3(9):1050-3. PubMed ID: 18758310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary toxicity associated with erlotinib.
    Liu V; White DA; Zakowski MF; Travis W; Kris MG; Ginsberg MS; Miller VA; Azzoli CG
    Chest; 2007 Sep; 132(3):1042-4. PubMed ID: 17873198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management.
    Ong CK; Tan WC; Chan LC; Abdul Razak M
    Med J Malaysia; 2012 Apr; 67(2):222-3. PubMed ID: 22822651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis.
    Um SJ; Lee SK; Yang DK; Son C; Roh MS; Kim KN; Lee KN; Choi PJ
    Clin Respir J; 2009 Jul; 3(3):181-4. PubMed ID: 20298401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
    Togashi Y; Masago K; Hamatani Y; Sakamori Y; Nagai H; Kim YH; Mishima M
    Lung Cancer; 2012 Aug; 77(2):464-8. PubMed ID: 22579408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
    Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
    Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nested case control study of proteomic biomarkers for interstitial lung disease in Japanese patients with non-small-cell lung cancer treated with erlotinib: a multicenter phase IV study (JO21661).
    Atagi S; Katakami N; Yoshioka H; Fukuoka M; Kudoh S; Ogiwara A; Imai M; Ueda M; Matsui S
    Clin Lung Cancer; 2013 Jul; 14(4):407-17. PubMed ID: 23490546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatal asymmetric interstitial lung disease after erlotinib for lung cancer.
    Ren S; Li Y; Li W; Zhao Z; Jin C; Zhang D
    Respiration; 2012; 84(5):431-5. PubMed ID: 22889962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.
    Wang KF; Chang CY; Chang SC; Liu YC; Yuan MK; Yang YH
    J Chin Med Assoc; 2013 Mar; 76(3):173-5. PubMed ID: 23497972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.
    Hata A; Katakami N; Kunimasa K; Yoshioka H; Fujita S; Kaji R; Tachikawa R; Tomii K; Imai Y; Iwasaku M; Ishida T
    Jpn J Clin Oncol; 2011 Dec; 41(12):1366-72. PubMed ID: 22058419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease.
    Fukui T; Otani S; Hataishi R; Jiang SX; Nishii Y; Igawa S; Mitsufuji H; Kubota M; Katagiri M; Masuda N
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):803-6. PubMed ID: 20035424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
    Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
    Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405).
    Akamatsu H; Inoue A; Mitsudomi T; Kobayashi K; Nakagawa K; Mori K; Nukiwa T; Nakanishi Y; Yamamoto N
    Jpn J Clin Oncol; 2013 Jun; 43(6):664-8. PubMed ID: 23585689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis.
    Abdel-Rahman O; Elhalawani H
    Future Oncol; 2015; 11(7):1109-22. PubMed ID: 25804125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.